anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The thiopurines 6-mercaptopurine (6MP) and 6-thioguanine (6TG) are widely used in the treatment of childhood acute lymphoblastic leukemia (ALL). They primarily exert their cytotoxicity through conversion into 6-thioguanine nucleotides (6TGN) that are incorporated into DNA. Interindividual variations in response to thiopurine therapy are influenced by genetically determined polymorphisms in the activity of the enzyme thiopurine methyltransferase (TPMT). TPMT competes with the formation of 6TGN, as it methylates the thiopurines (especially 6MP) and some of their metabolites. Approximately ten percent of all individuals are TPMT heterozygous, with one wild type and one low activity allele, and one in three hundred individuals are TPMT deficient with two low activity alleles. During the maintenance therapy phase of the treatment of childhood ALL, which may last several years, 6MP is given on a daily basis at a starting dose of 75 mg/m.sq./day, which is subsequently adjusted to a white blood cell count of 1.5-3.5 x109/L. We have previously demonstrated that the risk of relapse is reduced by more than 50%, but the risk of second cancer was increased 3-fold among TPMT low activity patients. Accordingly, the Nordic ALL2000 protocol recommended the dosing of 6MP to be based on the patients TPMT activity. In the present study of almost 1000 Nordic patients, we will explore whether this strategy of TPMT-based individualised 6MP dosing have benefitted the patients by reducing their risk of second cancer while preserving their low risk of relapse.
(A) Solid or liq. oral dosage forms, e.g. tablets, pills, capsules, powders, syrups or solns., contg. polyethylene glycol (PEG) with a molecular wt. of up to 35,000 are used to dissolve and enhance the excretion of harmful substances diffusing into the intestinal tract. (B) Lotions, creams, pastes, ointments, emulsions, shampoos or solns. contg. PEG are used topically to dissolve harmful substances which originate from the subcutaneous fatty tissue and are not absorbed through the skin, so that the dissolved substances can easily be removed by washing. USE/ADVANTAGE - PEG is a good solvent for halogenated hydrocarbons and is thus effective in scavenging toxins such as DDT, polychlorinated biphenyls, tetrachlorodibenzodioxin and dibenzofurans from contaminated humans or animals.
<P>PROBLEM TO BE SOLVED: To provide an endoscope image filing system capable of acquiring an image having an image quality equal to that of an image photographed by a specific model even when the image is photographed by a model different from the specific model.  <P>SOLUTION: A original image file part 308 stores a digital image which is outputted by an electronic scope 302 provided with an imaging device 301 and is equal to a digital image inputted to an image processing circuit 306. A library part 314 stores a plurality of image processing software. A selecting part 315 selects one from among the plurality of image processing software components stored in the library part. An image reproduction part 316 processes the digital image according to the selected image processing software component so that the digital image can be displayed.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Disproportionate non-communicable disease risk present in some ethnicities has been demonstrated and is amplified by increased weight gain. Relative to Malay and Caucasian populations, the prevalence of obesity increased sharply in people of Chinese and Indian ethnicity and diabetes risk is prevalent at a BMI of 21 (equivalent to a BMI \>25 in Caucasian populations). It was also speculated that Chinese Singaporean women are prone to metabolic syndrome at a lower BMI. This study will recruit two groups of postmenopausal women with different BMI's and to measure markers for metabolic syndrome. These participants will visit Clinical Nutrition Research Centre for a single session and will undergo a whole body scan and a regional scan of the lumbar spine and femoral neck with a bone densitometer and fasting baseline blood and urine samples collected. Dual Energy X-ray Absorptiometry (DEXA) scan will provide percentage fat mass, fat in gram, whole body bone mineral content and total body lean mass. From these, gynoid and android fat distribution will be derived and appendicular lean mass will be calculated and an index calculated using kg/m2 to give an indication of relative muscle mass. In addition blood and urine samples will be collected for metabolic risk analysis. Participants will be also be undergoing a Quantitative Computed Tomography (QCT) scan which will allow true volumetric measurements of the lumbar spine and proximal femur independent of the body size. Volumetric density values will be measured in Hounsfield units transformed into Bone Mineral Density measurements using a calibration phantom underneath the patient. Magnetic Resonance Imaging of the 3rd lumbar vertebra and the right hip will also be performed.
The invention relates to a traditional Chinese medicine Chinese yam/borax powder for treating infantile epilepsy, mainly solves the problems of poor curative effect and side effect in the existing medicines for treating anorexia. The powder is prepared by the following steps: taking 20-22 parts of Chinese yam, 3-5 parts of indico naturalis and 10-12 parts of borax; and baking, and grinding together into the fine powder. A dose of 1-3g is taken for children at the age of 1-3, and a dose of 5-8g is taken for children at the age of 4-6; and the powder is taken once respectively in the morning and at night. Patients who are not subjected epilepsy for half an year should take the powder twice a day. Patients who are not subjected epilepsy for one year should take the powder once a day. The total effective rate for treating infantile epilepsy is higher than 95%, and the cure rate is higher than 80%. The powder has no toxic or side effect.
The invention belongs to the technical field of Tff1 research, and particularly discloses application of Tff1 in vascular diseases. Tff1 is applied to the preparation of drugs for preventing and treating vascular related diseases. The medicine for preventing and treating relevant vascular diseases comprises an effective component Tff 1. Use of Tff1 as an inhibitor of vascular smooth muscle cell apoptosis. An inhibitor of vascular smooth muscle apoptosis, comprising an effective ingredient of Tff 1. A vascular spandex degradation inhibitor comprises an effective component Tff 1. The invention enables the trefoil factor 1 to have a new application approach; provides a new medicine for preventing and treating vascular diseases; trefoil factor 1 plays a key role in inhibiting vascular smooth muscle cell apoptosis and inhibiting vascular elastic fiber degradation.
During the controlled epilepsy trials in patients older than 12 years of age receiving doses of gabapentin up to 1800 mg daily, somnolence, dizziness, and ataxia were reported at a greater rate in patients receiving gabapentin compared to placebo: i.e., 19% in drug versus 9% in placebo for somnolence, 17% in drug versus 7% in placebo for dizziness, and 13% in drug versus 6% in placebo for ataxia. In these trials somnolence, ataxia and fatigue were common adverse reactions leading to discontinuation of gabapentin in patients older than 12 years of age, with 1.2%, 0.8% and 0.6% discontinuing for these events, respectively.

During the controlled trials in patients with post-herpetic neuralgia, somnolence and dizziness were reported at a greater rate compared to placebo in patients receiving gabapentin, in dosages up to 3600 mg per day: i.e., 21% in gabapentin-treated patients versus 5% in placebo-treated patients for somnolence and 28% in gabapentin-treated patients versus 8% in placebo-treated patients for dizziness. Dizziness and somnolence were among the most common adverse reactions leading to discontinuation of gabapentin.

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when gabapentin is used with other drugs with sedative properties because of potential synergy. In addition, patients who require concomitant treatment with morphine may experience increases in gabapentin concentrations and may require dose adjustment [see DRUG INTERACTIONS (7.2)].
Cholesterol is an essential lipid molecule in mammalian cells. It is not only involved in the formation of cell membranes but also serves as a raw material for the synthesis of bile acids, vitamin D, and steroid hormones. Additionally, it acts as a covalent modifier of proteins and plays a crucial role in numerous life processes. Generally, the metabolic processes of cholesterol absorption, synthesis, conversion, and efflux are strictly regulated. Excessive accumulation of cholesterol in the body is a risk factor for metabolic diseases such as cardiovascular disease, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD). In this review, we first provide an overview of the discovery of cholesterol and the fundamental process of cholesterol metabolism. We then summarize the relationship between dietary cholesterol intake and the risk of developing MASLD, and also the animal models of MASLD specifically established with a cholesterol-containing diet. In the end, the role of cholesterol-induced inflammation in the initiation and development of MASLD is discussed.
Females and males 9-26 years old who are vaccinated with GARDASIL in usual practice. The GARDASIL vaccination series consists of three 0.5-mL intramuscular injections. The second and third doses are to be administered 2 months and 6 months after the first dose, respectively.
This invention relates, at least in part, to engineered antimicrobial probiotics for the prevention or treatment of Clostridia perfringens-induced necrotic enteritis in animals and related methods. In an embodiment, a composition for treatment of chickens is included. The composition can include a bacterium originally isolated from the small intestinal tract of healthy chickens and can be genetically engineered with two exogenous polynucleotides. A first exogenous polynucleotide can include a heterologous promoter and a polynucleotide that encodes an antimicrobial protein. A second exogenous polynucleotide can include a heterologous promoter and a polynucleotide that encodes proteins that function to secrete the antimicrobial protein to the extracellular environment. In an embodiment, the antimicrobial peptide can be effective in killing C. perf. inside the gastrointestinal tract of chickens.
Group A. The Smart Equitest program was used with a protocol of 10 exercises per session, which were customized depending on each patient´s deficit. The exercises involve visual biofeedback together with sensitive, real-time monitoring of movement. In some exercises, patients must maintain their center of gravity (COG) over the base of support, while in others the COG must be moved to a series of targets. In addition, the support surface and/or visual surround may also move in response to the patient´s own movement. The exercise difficulty was progressively increased throughout the rehabilitation sessions. The duration of each session was approximately 15 minutes. The distribution of sessions was one per day and five per week (2 weeks).
Patients with recently diagnosed brain metastatic lesion(s) will be recruited based on MRI with or without histological confirmation, per standard of care. All patients will undergo an 18F-fluciclovine head PET/CT scan prior to treatment for brain metastatic lesions, post treatment, and 3 years post treatment.
Post-spinal anesthesia hypotension is a frequent complication during spinal anesthesia for cesarean section. The incidence of post-spinal anesthesia hypotension is as high as 62.1-89.7% if prophylactic measures are not taken. Colloid fluid coload has been highly demonstrated for prevention and/or treatment of post-spinal anesthesia hypotension. In addition, there's some evidence that prophylactic infusion of norepinephrine could effectively reduce the incidence of post-spinal anesthesia hypotension in parturients undergoing cesarean section. However, the ED50 and ED90 for an effective 6% Hydroxyethyl starch (130/0.4) or crystalloid coload combined with prophylactic norepinephrine infusion dose for postspinal anesthesia hypotension is still unknown. The purpose of this study is to investigate the ED50 and ED90 for an effective 6% Hydroxyethyl starch (130/0.4) or crystalloid coload combined with prophylactic norepinephrine infusion dose for postspinal anesthesia hypotension in patients undergoing cesarean section.
The invention discloses an information processing method and an information processing system, which can reduce the time and effort required by medical staff in judging heart failure stage. According to an aspect of the present invention, there is provided an information processing system. The information processing system is configured to execute the reading step and the judging step. The reading step reads the 1 st electrocardiogram including the user's electrocardiogram, which is input. The judging step judges the heart failure stage of the user based on the 1 st electrocardiogram and reference information. The reference information is information indicating a relationship between a2 nd electrocardiogram including an electrocardiogram at the stage of heart failure judged by a doctor and a characteristic amount of heart failure obtained in advance. The reference information is a learned model in which the feature quantity of heart failure is learned from the 2 nd electrocardiogram. The learned model is a model learned from the contents judged by the judging step and corresponding clinical data.
Participants will receive lifestyle intervention which includes modern dietary exercise modifications. Participants will receive this treatment for a 8-session treatment course and 4-session follow-up course.
Disclosed herein are methods and systems of providing computerized medical communications. An exemplary method includes receiving patient account data associated with a patient and generating a plurality of questions configured to elicit responses from the patient. The method transmits the generated plurality of questions to the patient and subsequently receives response data from the patient wherein the response data is generated based on the transmitted plurality of questions. Virtual chart data is generated with a virtual chart logic based on the received response data. Provider data comprising subscribed providers is received and a secure session is generated between the patient and a provider based on at least the patient account data and the provider data. The virtual chart data is provided to the medical care provider during the session; and, upon termination, a method of acceptance is provided to the patient to indicate an approval of the secured session termination.
Infusions of Prochymal on days 42-45, 84-87, and 126-129 after first infusion in Protocol 603. Each infusion of PROCHYMAL (remestemcel-L) will contain 200 million cells.
We would like to conduct a prospective study to evaluate to therapeutic effect of oral valacyclovir for the patients with IC/BPS. The diagnosis of IC/BPS was made through following the clinical symptom index of the American Urological Association guideline. The IC/BPS patients with concurrent urological diseases, such as neurogenic voiding dysfunction, ketamine cystitis or acute bacterial cystitis in recent one month would be excluded. The IC/BPS patients with possibility of pregnancy also would be rule out.

At first, the enrolled patients would be investigated for urinary analysis and culture to rule out current bacteriuria. The enrolled patients would receive a comprehensive medical history review. A pregnancy test would be performed for women of childbearing potential. The patients would be asked to provide urine sample to urinary virus investigation before the treatment. The IC/BPS patients would be investigated for baseline clinical symptoms questionnaire including VAS, QoL, ICPI, ICSI, and OSS. The parameters in the VUDS report also would be record. The Informed consent would be obtained from all individual participants before the intervention. Due to higher bioavailability, we would use valacyclovir in this study. The dose of valacyclovir we use is according to previous valacyclovir study for genital HSV infection. \[18\] According previous valacyclovir study for chronic recurrence herpesvirus infection disease, long-term therapy of oral valacyclovir \< 1000mg/day should be effective and safe; the safety profiles of valacyclovir and placebo were similar. All of our patients would receive open-label oral valacyclovir 500 mg twice per day for 4 weeks.

We estimate to enroll 30 IC/BPS patients with evidence of EBV infection in bladder into this study. After the beginning of valacyclovir therapy, the patients would receive a telephone interview to evaluated current symptoms changes at first and second weeks. The overall improvement of current therapy would be assessed with Global Response Assessment (GRA) (3: symptoms free, 2: \>50% symptoms improvement, 1: 25-50% symptoms improvement, 0: 0-25% symptoms improvement, -1: symptoms worse). The GRA, VAS, and any adverse effect would be investigated in the telephone interview. After the full 4 weeks treatment, the patients would be asked to back to our clinic. All symptoms questionnaire (GRA, VAS, QoL, ICPI, ICSI, and OSS) and adverse effect would be evaluated again. The patients would be asked to provide urine sample again. The primary endpoint of this study is the GRA at 4 weeks. The secondary endpoints include the changes of VAS, VAS, QoL, ICPI, ICSI, and OSS between baseline and end of the study. The following figure showed the study flow diagram.
The present invention relates generally to Leukemia Inhibitory Factor (LIF) variants. More particularly, the present invention provides cytokine antagonists and agonists. Even more particularly, the present invention provides agonists and antagonists of cytokines which act via the Leukemia Inhibitory Factor (LIF) receptor a-chain (LIFR) and gp130 signalling system. The agonists and antagonists are based on modified forms of LIF. The agonists and antagonists of the present invention are also useful as targets for developing or screening for chemical mimetics and in particular small chemical mimetics of the modified LIF molecules. The agonists and antagonists of the present invention are useful agents in the treatment and/or prophylaxis of cytokine-mediated conditions including inflammation, cancer growth, fertility and pregnancy, or for the culturing of embryonic stem cells. The present invention further contemplates a method for modulating cytokine-mediated physiological or disease conditions such as inflammation, cancer, fertility or pregnancy as well as compositions comprising the antagonists.
PROBLEM TO BE SOLVED: To judge and evaluate the stimulus development under the application of light of a makeup decoration by using a specific amount of peroxide being generated at sebum by applying light under the coexistence with the sebum. SOLUTION: A makeup decoration is mixed into sebum or its similar matter, light such as ultraviolet rays is applied to it and the amount of generated peroxide is measured, thus using the amount of generated as an index. More specifically, the sebum is obtained by gathering naturally secreted sebum or using skin as it is and collecting sebum after applying light. In the case of the skin, human skin is preferable, and a plurality of panelers are used to reduce personal difference. The foundation or the like of a specimen are applied to the specimen on the sebum by 0.01 g/30 cm<2> , and the quantity of light to be applied is set with the amount of ultraviolet rays being matched to the conditions of solar light for easily creating peroxide as an index.  After light is applied, a sebum constituent is collected from a site by a solvent, the peroxide valence is measured, and lesser TBA value in reference to 55 is evaluated as less development of stimulus.
Image viewing systems, such as clinical medical image viewing systems, can be equipped for image browsing. Such systems may benefit from synchronized image browsing. A method can include displaying a plurality of related images at a same time. The method can also include synchronizing the related images with respect to an operation performed on one of the images. Likewise, an apparatus can include a user interface configured to display a plurality of related images at a same time. The apparatus also includes a synchronizer configured to synchronize the related images with respect to an operation performed on one of the images.
The present invention comprises a method for delivering pharmaceutical and/or imaging agents within and/or through the dermal, mucosal and other cellular membranes, and across the blood-brain barrier, utilizing a fusogenic protein. The fusogenic protein is associated with a phospholipid membrane, such as a liposome. The liposome may include dioleoylphosphatidylserine, a negatively charged long-chain lipid. Alternatively, the liposome is comprised of a mixture of negatively charged long-chain lipids, neutral long- chain lipids, and neutral short-chain lipids. Preferred fusogenic proteins include saposin C and other proteins, polypeptides and peptide analogs derived from saposin C. The active agent contained within the liposome may comprise biomolecules and/or organic molecules. This technology can be used for both cosmetic and medicinal applications in which the objective is delivery of the active agent within and/or beneath biological membranes or across the blood-brain barrier and neuronal membranes.
Renal Toxicity

Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.

Renal toxicity has also been seen in patients in whom renal prostaglandins have a compensatory role in the maintenance of renal perfusion. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation. Patients at greatest risk of this reaction are those with impaired renal function, dehydration, hypovolemia, heart failure, liver dysfunction, those taking diuretics and ACE-inhibitors or ARBs, and the elderly. Discontinuation of NSAID therapy is usually followed by recovery to the pretreatment state.

No information is available from controlled clinical studies regarding the use of diclofenac sodium in patients with advanced renal disease. The renal effects of diclofenac sodium may hasten the progression of renal dysfunction in patients with preexisting renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating diclofenac sodium. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use of diclofenac sodium [ see Drug Interactions (7)]. Avoid the use of diclofenac sodium in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If diclofenac sodium topical solution is used in patients with advanced renal disease, monitor patients for signs of worsening renal function. 

Hyperkalemia

Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment. In patients with normal renal function, these effects have been attributed to a hyporeninemic-hypoaldosteronism state.